Know Cancer

forgot password

Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With Estradiol > 25 pg/mL

Phase 3
18 Years
Open (Enrolling)

Thank you

Trial Information

Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With Estradiol > 25 pg/mL

Inclusion Criteria:

1. Women with baseline estradiol >25 pg/mL

2. Histologically- or cytologically-confirmed diagnosis of NSCLC.

3. ECOG performance score (PS) of 0, 1, or 2.

4. Patients must meet one of the following criteria have either (1) Recurrent disease
following completion of radiation or surgery, (2) Stage IIIB disease and not be a
candidate for combined modality therapy (primary radiation therapy or surgery), or
(3) Stage IV disease.

5. At least 18 years of age.

6. Adequate bone marrow function

7. Adequate renal function

8. Adequate hepatic function

9. Life expectancy ≥12 weeks

Exclusion Criteria:

1. Known hypersensitivity to the excipients or the study drug (either CT-2103,
paclitaxel, or carboplatin that the patient will receive.

2. Evidence of small cell carcinoma, carcinoid, or mixed small cell/non-small cell

3. Weight loss >10% in previous 6 months

4. LDH > 2.5X IULN

5. Both LDH > 1.5X IULN and ≥ 5% weight loss in previous 6 months

6. BMI >35

7. Any prior systemic chemotherapy for the treatment of lung cancer. This includes
systemic radiosensitizers used to treat brain metastases and any biologic agent.

8. Local palliative radiotherapy < 7 days before randomization.

9. Radiation with curative intent < 30 days before randomization.

10. Concurrent primary malignancies except for carcinoma in situ or non-melanoma skin

11. Grade 2 or greater neuropathy.

12. Evidence of significant unstable neurological symptoms within the 4 weeks before
study randomization.

13. Clinically significant active infection for which active therapy is underway.

14. Investigational therapy within 4 weeks before randomization, unless local
requirements are more stringent.

15. Unstable medical conditions including unstable angina or myocardial infarction within
the past 6 months before randomization.

16. Pregnant women or nursing mothers.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:


Outcome Time Frame:

up to 3 years post treatment

Safety Issue:


Principal Investigator

Jack W. Singer, M.D.

Investigator Role:

Study Director

Investigator Affiliation:

Cell Therapeutics


United States: Food and Drug Administration

Study ID:




Start Date:

September 2007

Completion Date:

January 2014

Related Keywords:

  • women
  • CT-2103
  • paclitaxel
  • carboplatin
  • Carcinoma, Non-Small-Cell Lung



New York Medical College Valhalla, New York  10595
Virginia Mason Medical Center Seattle, Washington  98111
Hartford Hospital Hartford, Connecticut  06102-5037
Southwest Regional Cancer Center Austin, Texas  78705
Stanford Cancer Center Stanford, California  94305-5824
Cancer Care Center New Albany, Indiana  47150
Arena Oncology Associates Great Neck, New York  11021
Lincoln Medical and Mental Health Center Bronx, New York  10451
Southwest Cancer Care Poway, California  92064
Mary Crowley Medical Research Center Dallas, Texas  75246
Northern Utah Associates Ogden, Utah  84403
Broward Oncology Associates Ft. Lauderdale, Florida  33308
Mayo Clinic Scottsdale, Arizona  
Providence St. Joseph Medical Center Burbank, California  91505
Pasco Pinellas Cancer Center New Port Richey, Florida  34652
St. Louis University St. Louis, Missouri  63110
Las Vegas Cancer Center Las Vegas, Nevada  89102
Loyola University Maywood, Illinois  60153
The Family Cancer Center Collierville, Tennessee  38017
VA Sierra Nevada Health Care System Reno, Nevada  89502
Kansas City Cancer Center Kansas City, Kansas  66112
Vita Hematology Oncology, P.C. Bethlehem, Pennsylvania  18015
University of Oklahoma Health Science Center Oklahoma City, Oklahoma  73104
Hematology Oncology Consultants Naperville, Illinois  60540
Joliet Oncology Hematology Associates, Ltd Joliet, Illinois  60435
Providence Medical Group Terre Haute, Indiana  47802
Lone Star Oncology Consultants Austin, Texas  78759
Richmond University Medical Center Staten Island, New York  10310-1699
Memorial Cancer Institute Pembroke Pines, Florida  33028
Columbia Comprehensive Cancer Care Clinics Columbia, Missouri  65201
Mid-South Cancer Center Germantown, Tennessee  38138
Horizon Institute for Clinical Research Hollywood, Florida  33021
Scottsdale Medical Specialists Scottsdale, Arizona  85258
Hattiesburg Clinic Hattiesburg, Mississippi  39401
Hembree Regional Cancer Center Fort Smith, Arkansas  72903
Clinical Trials & Research Institute Montebello, California  90640
Family Medicine of Vincennes Clinical Trials Center Vincennes, Indiana  47591
Henry Ford Health System, Josephine Ford Cancer Center Detroit, Michigan  48202
W. Michigan Regional Cancer & Blood Center Freesoil, Michigan  49411
St Alexius Medical Center Bismark, North Dakota  58501
Blood and Cancer Center Canfield, Ohio  44406
Aultman Hospital Clinical Trials Canton, Ohio  44710
UIMA, Inc / University of Cincinnati-Barrett Cancer Center Cincinnati, Ohio  45267
Cancer Outreach Associates, LLC Arlington, Virginia  24211